169 related articles for article (PubMed ID: 35583393)
1. A patent review of anticancer CDK2 inhibitors (2017-present).
Said MA; Abdelrahman MA; Abourehab MAS; Fares M; Eldehna WM
Expert Opin Ther Pat; 2022 Aug; 32(8):885-898. PubMed ID: 35583393
[TBL] [Abstract][Full Text] [Related]
2. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
Roskoski R
Pharmacol Res; 2016 May; 107():249-275. PubMed ID: 26995305
[TBL] [Abstract][Full Text] [Related]
3. Inhibitors of Cyclin-Dependent Kinase 1/2 for Anticancer Treatment.
Mou J; Chen D; Deng Y
Med Chem; 2020; 16(3):307-325. PubMed ID: 31241436
[TBL] [Abstract][Full Text] [Related]
4. Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs.
Roskoski R
Pharmacol Res; 2019 Jan; 139():471-488. PubMed ID: 30508677
[TBL] [Abstract][Full Text] [Related]
5. Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update.
Tadesse S; Caldon EC; Tilley W; Wang S
J Med Chem; 2019 May; 62(9):4233-4251. PubMed ID: 30543440
[TBL] [Abstract][Full Text] [Related]
6. Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).
Malínková V; Vylíčil J; Kryštof V
Expert Opin Ther Pat; 2015; 25(9):953-70. PubMed ID: 26161698
[TBL] [Abstract][Full Text] [Related]
7. Multifaceted regulation of cell cycle progression by estrogen: regulation of Cdk inhibitors and Cdc25A independent of cyclin D1-Cdk4 function.
Foster JS; Henley DC; Bukovsky A; Seth P; Wimalasena J
Mol Cell Biol; 2001 Feb; 21(3):794-810. PubMed ID: 11154267
[TBL] [Abstract][Full Text] [Related]
8. Cell cycle molecular targets in novel anticancer drug discovery.
Buolamwini JK
Curr Pharm Des; 2000 Mar; 6(4):379-92. PubMed ID: 10788588
[TBL] [Abstract][Full Text] [Related]
9. Palbociclib triggers apoptosis in bladder cancer cells by Cdk2-induced Rad9-mediated reorganization of the Bak.Bcl-xl complex.
Zhang G; Ma F; Li L; Li J; Li P; Zeng S; Sun H; Li E
Biochem Pharmacol; 2019 May; 163():133-141. PubMed ID: 30772267
[TBL] [Abstract][Full Text] [Related]
10. Clinical CDK4/6 inhibitors induce selective and immediate dissociation of p21 from cyclin D-CDK4 to inhibit CDK2.
Pack LR; Daigh LH; Chung M; Meyer T
Nat Commun; 2021 Jun; 12(1):3356. PubMed ID: 34099663
[TBL] [Abstract][Full Text] [Related]
11. Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta.
Reynisdóttir I; Polyak K; Iavarone A; Massagué J
Genes Dev; 1995 Aug; 9(15):1831-45. PubMed ID: 7649471
[TBL] [Abstract][Full Text] [Related]
12. Psoriatic epidermis is associated with upregulation of CDK2 and inhibition of CDK4 activity.
Henri P; Prevel C; Pellerano M; Lacotte J; Stoebner PE; Morris MC; Meunier L
Br J Dermatol; 2020 Mar; 182(3):678-689. PubMed ID: 31145809
[TBL] [Abstract][Full Text] [Related]
13. Eco-friendly sequential one-pot synthesis, molecular docking, and anticancer evaluation of arylidene-hydrazinyl-thiazole derivatives as CDK2 inhibitors.
El-Naggar AM; El-Hashash MA; Elkaeed EB
Bioorg Chem; 2021 Mar; 108():104615. PubMed ID: 33484942
[TBL] [Abstract][Full Text] [Related]
14. Activation of cdk4 and cdk2 during rat liver regeneration is associated with intranuclear rearrangements of cyclin-cdk complexes.
Jaumot M; Estanyol JM; Serratosa J; Agell N; Bachs O
Hepatology; 1999 Feb; 29(2):385-95. PubMed ID: 9918914
[TBL] [Abstract][Full Text] [Related]
15. Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2.
Prall OW; Sarcevic B; Musgrove EA; Watts CK; Sutherland RL
J Biol Chem; 1997 Apr; 272(16):10882-94. PubMed ID: 9099745
[TBL] [Abstract][Full Text] [Related]
16. Advances in Pyrazole Based Scaffold as Cyclin-dependent Kinase 2 Inhibitors for the Treatment of Cancer.
Shaikh J; Patel K; Khan T
Mini Rev Med Chem; 2022; 22(8):1197-1215. PubMed ID: 34711160
[TBL] [Abstract][Full Text] [Related]
17. Cyclin-dependent kinase-2 as a target for cancer therapy: progress in the development of CDK2 inhibitors as anti-cancer agents.
Chohan TA; Qian H; Pan Y; Chen JZ
Curr Med Chem; 2015; 22(2):237-63. PubMed ID: 25386824
[TBL] [Abstract][Full Text] [Related]
18. A patent review of cyclin-dependent kinase 7 (CDK7) inhibitors (2018-2022).
Kovalová M; Baraka JP; Mik V; Jorda R; Luo L; Shao H; Kryštof V
Expert Opin Ther Pat; 2023 Feb; 33(2):67-87. PubMed ID: 36975020
[TBL] [Abstract][Full Text] [Related]
19. Discovery of novel macrocyclic derivatives as potent and selective cyclin-dependent kinase 2 inhibitors.
Niu P; Tao Y; Meng Q; Huang Y; Li S; Ding K; Ma D; Ye Z; Fan M
Bioorg Med Chem; 2024 Apr; 104():117711. PubMed ID: 38583237
[TBL] [Abstract][Full Text] [Related]
20. Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells.
Kang J; Sergio CM; Sutherland RL; Musgrove EA
BMC Cancer; 2014 Jan; 14():32. PubMed ID: 24444383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]